Literature DB >> 28844818

Guadecitabine: a new therapeutic option for acute myeloid leukaemia?

Felicetto Ferrara1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28844818     DOI： 10.1016/S1470-2045(17)30614-9

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  3 in total

Review 1.  Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML.

Authors:  Anne Sophie Kubasch; Uwe Platzbecker
Journal:  Cancers (Basel)       Date:  2018-05-24       Impact factor: 6.639

2.  Down-regulation of miR-29c is a prognostic biomarker in acute myeloid leukemia and can reduce the sensitivity of leukemic cells to decitabine.

Authors:  Li-Juan Tang; Guo-Kang Sun; Ting-Juan Zhang; De-Hong Wu; Jing-Dong Zhou; Bei-Bei Ma; Zi-Jun Xu; Xiang-Mei Wen; Qin Chen; Dong-Ming Yao; Jun Qian; Ji-Chun Ma; Jiang Lin
Journal:  Cancer Cell Int       Date:  2019-07-10       Impact factor: 5.722

3.  The Cancer/Testis Antigen Gene VCX2 Is Rarely Expressed in Malignancies but Can Be Epigenetically Activated Using DNA Methyltransferase and Histone Deacetylase Inhibitors.

Authors:  Mie K Jakobsen; Sofie Traynor; Mette Stæhr; Pascal G Duijf; Aaraby Y Nielsen; Mikkel G Terp; Christina B Pedersen; Per Guldberg; Henrik J Ditzel; Morten F Gjerstorff
Journal:  Front Oncol       Date:  2021-02-09       Impact factor: 6.244
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.